Purvin Valerie, Kawasaki Aki, Smith Kyle H, Kesler Anat
From Midwest Eye Institute and Indiana University Medical Center, Departments of Ophthalmology and Neurology (VP, A Kawasaki), Indianapolis, Indiana; Scott and White Eye Institute (KHS), Temple, Texas; and Tel Aviv Sourasky Medical Center, Department of Ophthalmology, Neuro-ophthalmology Unit (A Kesler), Tel Aviv, Israel.
Medicine (Baltimore). 2006 Mar;85(2):82-85. doi: 10.1097/01.md.0000209337.59874.aa.
A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described. We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug. In 1 case the drug appears to have exacerbated underlying myasthenic weakness, whereas in the other 3 cases, de novo antibody formation appears to be most likely. In each case, some degree of recovery followed discontinuation of the statin medication.
最近有几例个别病例报告表明，他汀类药物治疗可能与肌无力综合征有关，但这种关联尚未得到充分描述。我们报告了4例在开始使用他汀类药物治疗后2周内出现重症肌无力症状的患者。在1例中，药物似乎加重了潜在的肌无力，而在其他3例中，最有可能是出现了新的抗体形成。在每例中，停用他汀类药物后均有一定程度的恢复。
